A double-blind, placebo-controlled, randomized trial of XP-828L (800 mg) on the quality of life and clinical symptoms of patients with mild-to-moderate psoriasis

Alternative Medicine Review

Volumn 13, Issue 2, 2008, Pages 145-152

  Drouin, Rejean ^a,b   Moroni, Olivier ^b,c   Cantin, Kim ^b,d   Juneau, Christina ^b,d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b R and D Advitech ^*  (Canada)

^c Nutraceuticals and Functional Foods Institute (INAF)

^d UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; DERMYLEX; PLACEBO; XP 828L;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ADMINISTRATION, ORAL; ADULT; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MILK PROTEINS; PSORIASIS; QUALITY OF LIFE;

EID: 47549105899     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. National Psoriasis Foundation Benchmark Survey. http://www.psoriasis.org/ files/pdfs/press/npfsurvey.pdf [Accessed April 3, 2006]
2. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370:272-284.
3. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB Jr. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003;9:2.
4. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004;140:408-414.
5. Drouin R, Lamiot E, Cantin K, et al. XP-828L (Dermylex), a new whey protein extract with potential benefit for mild to moderate psoriasis. Can J Physiol Pharmacol 2007;85:943-951.
6. Poulin Y, Bissonnette R, Juneau C, et al. XP-828L in the treatment of mild to moderate psoriasis: randomized, double-blind, placebo-controlled study. J Cutan Med Surg 2006;10:241-248.
7. Poulin Y, Pouliot Y, Lamiot E, et al. Safety and efficacy of a milk-derived extract in the treatment of plaque psoriasis: an open-label study. J Cutan Med Surg 2005;9:271-275.
8. Juneau C, Drouin R, Moroni O. Process for the manufacture of an anti-inflammatory composition. Patent No. 13431-15USPR, 2007.
9. Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005;125:659-664.
10. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004;51:563-569.
11. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64:ii65-68.
12. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64:ii18-23.
13. Gupta MA, Schork NJ, Gupta AK, et al. Suicidal ideation in psoriasis. Int J Dermatol 1993;32:188-190.
14. Kirby B, Richards HL, Woo P, et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001;45:72-76.
15. Mazzotti E, Picardi A, Sampogna F, et al. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003;149:318-322.
16. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 2000;19:1745-1754.
17. Wahl SM, Chen W. Transforming growth factor-beta-induced regulatory T cells referee inflammatory and autoimmune diseases. Arthritis Res Ther 2005;7:62-68.
18. Li MO, Wan YY, Sanjabi S, et al. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99-146.
19. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001;7:1118-1122.
20. Fantini MC, Becker C, Monteleone G, et al. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004;172:5149-5153.
21. Flanders KC, Burmester JK. Medical applications of transforming growth factor-beta. Clin Med Res 2003;1:13-20.
22. Prud'homme GJ, Piccirillo CA. The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases. J Autoimmun 2000;14:23-42.
23. Zimecki M, Kruzel ML. Milk-derived proteins and peptides of potential therapeutic and nutritive value. J Exp Ther Oncol 2007;6:89-106.
24. Marshall K. Therapeutic applications of whey protein. Altern Med Rev 2004;9:136-156.